Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Companies can stop studies before reaching projected enrollment numbers. It could be a decision based on a planned interim analysis (IA) or it could be for ‘administrative’ reasons. The latter may not indicate that a company has fallen on hard Continue reading THE UTILITY OF FUTILITY
Vancomycin got a bad reputation since the early 90ies when it became clear that it was slow to provide clinical improvement and microbiologic cure in MRSA patients. It was associated with prolonged bacteremia even when combined with rifampin [1]. And for MSSA, Continue reading Vancomycin vs TMP/SMX for MRSA – Not the Final Word